Alzheimer's Disease And Dementia
Fluorine 18 fluorodeoxyglucose PET of the brain can be used to develop a deep learning algorithm for early prediction of AD that has high specificity and sensitivity.
Individuals with Alzheimer disease have abnormalities and reductions in gene expression in the parahippocampal gyri that map to genes associated with the insulin receptor signaling pathway.
Approximately 5.5 million Americans have Alzheimer disease or dementia.
The results highlight the importance of evaluating and monitoring cognitive function in individuals with recent critical illness or major infections, especially if they are already at risk for dementia.
Grand multiparity was associated with significantly worse Mini-Mental State Examination scores compared with those with 1 to 4 completed pregnancies.
There is a positive association between residential levels of air pollution and being diagnosed with dementia.
Age, sex and apolipoprotein E genotype can identify groups at high 10-year risk for Alzheimer disease and all dementia.
Multiple pathways account for the age-related increases in dementia risk.
The burden of Alzheimer disease and related dementias is expected to increase to 3.3% in the United States by 2060.
Retinal microvascular abnormalities are identified in cognitively healthy individuals who have biomarkers positive for Alzheimer disease.
Positron emission tomographic imaging can directly measure synaptic loss with Alzheimer disease.
Currently, there are no approved treatments for behavioral symptoms in Alzheimer disease.
Investigators reviewed data from patients aged 45 to 64 years who were enrolled in the Atherosclerosis Risk in Communities Study and who attended additional visits for cognitive function evaluation and repeat cardiovascular risk factor assessment.
An international team of investigators assessed the ability of flutemetamol F 18-labeled PET and other biomarkers to predict risk of clinical progression from amnestic mild cognitive impairment to probable Alzheimer disease.
For an unselected memory clinic cohort, amyloid PET results are associated with changes in etiology, diagnostic confidence, and patient treatment.
While hundreds of published reports have made an argument for an association between Alzheimer disease and bacteria and viruses, the suggestion of a viral contribution to Alzheimer disease has not always been well received by the greater research community.
Phase 3 clinical trials for lanabecestat (Eli Lilly and AstraZeneca), an investigational Alzheimer disease treatment, are being discontinued for futility.
The risk of dementia is increased in 50-year-olds with blood pressure ≥130 mm Hg, which is below the current threshold for hypertension.
The lifetime risks of Alzheimer disease dementia vary considerably by age, gender, and the preclinical or clinical disease state.
There was an observable pattern with combined polyphenol intake and risk for dementia in the study cohort.
Janssen announced that the Company will no longer continue studying atabecestat, an investigational treatment for asymptomatic patients at risk for developing Alzheimer disease.
These results suggest that antipsychotic exposure has no impact on relative mortality.
Multimarker inflammatory biosignatures are expected to facilitate diagnosis and predict treatment outcomes for various central nervous system disorders, particularly Alzheimer disease and major depressive disorder.
Methylphenidate demonstrated an improvement in apathy vs placebo when measured by the apathy evaluation scale, in addition, methylphenidate showed possible improvement in cognition.
Use of anticholinergic drugs may be tied to a future diagnosis of dementia.
Additional examination of these relationships is warranted to help clarify the complex biologic and psychosocial interactions among Alzheimer disease, malignant melanoma, and nonmelanoma skin cancer.
Results showed that after 18-months, there was no significant statistical difference in cognitive or functional outcomes between those patients taking azeliragon and the placebo group.
About half of adults surveyed expect a man with mild Alzheimer dementia to be discriminated against.
Findings show lower post-surgical mortality among patients with Alzheimer's disease.
Molecular markers can identify changes associated with the disease before clinical onset for young adults with autosomal dominant AD.
Neurology Advisor Articles
- US Opioid Overdose Deaths Reach Record Number
- Migraine Treatment in the ED: Overcoming Our Penchant for Opioids
- Erenumab as a Therapy for Hard to Treat Episodic Migraine
- Abnormalities in Genes Linked to IRSP in Alzheimer Disease
- Recommended Levels of Cardiovascular Risk Factors Associated With Cerebral Vessel Density, Flow
- New Diagnostic Criteria for Neurosarcoidosis: What You Need to Know
- Guideline for Diagnosis and Treatment of Idiopathic Intracranial Hypertension
- Guidelines on the Use of OnabotulinumtoxinA for Chronic Migraine
- Ivy League Rule Change Linked to Fewer Concussions During NCAA Football Games
- Addressing Levodopa-Resistant Parkinson Disease
- High Daily Stress Linked to Migraine Prevalence in Women
- Researchers Identify Coffee Component That May Provide Neuroprotection
- Functional Imaging in Movement Disorders: Diagnostic Advantages
- Dextroamphetamine Plus Physical Therapy Nonsuperior to Placebo for Improving Post-Stroke Motor Recovery
- Nusinersen May Be Effective for Short-Term Motor Function Improvements in Spinal Muscular Atrophy